Search

everythinglearnresearchcommunity

for

Search:↓

A user shared their 2-year progress using finasteride every other day with no side effects. Others discussed their experiences, shedding cycles, and patience with the treatment.

The user is using a compounded foam with Latanoprost 0.01% and Finasteride 0.1%, averaging 3ml per week, and is considering whether to add oral finasteride despite concerns about side effects. They are also contemplating switching to 1mg oral finasteride and oral minoxidil for simplicity and effectiveness.

Breezula's phase 3 results are expected in July or August, with commercialization possibly in two years. There are concerns about delays and effectiveness, and the cost may be high.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

The conversation discusses anticipation for CB-03-01, a potential new hair loss treatment that may be more effective and have a cleaner safety profile than finasteride. Users are hopeful but cautious, discussing current treatments like minoxidil, nizoral, and dermarolling, and the possibility of combining them with CB-03-01 for better results.

Finasteride and Dutasteride will remain accessible in the EU despite objections from France and Belgium. Users discuss the ease of obtaining these medications in different countries and express relief and support for the EU's decision.

Exploring treatments for hair loss, such as finasteride, minoxidil, RPB (an unknown acronym), vitamin D levels, and derma rolling.

User creates 0.1% topical finasteride solution using Alfatradiol Avixis base. Seeks help to ensure alfatradiol base dissolves finasteride.

The conversation discusses the use of Verteporfin in treating hair loss. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

User wants to try Eucapil for hair loss but experienced side effects from finasteride. Seeks feedback on Eucapil's potential side effects.

The conversation discusses a topical finasteride therapy with hydrocortisone butyrate, estrone base, and breviline. A user suggests oral finasteride as a superior option.

The FDA will now require only one clinical trial for drug approval, potentially speeding up the release of hair loss treatments like PP405. Pelage is expected to present full results of PP405 Phase 2a trials and move to Phase III in mid-2026.

A user stopped using RU58841 after discovering their girlfriend's unplanned pregnancy, expressing concern about potential harm to the baby. Others advised consulting a doctor, waiting for health scans, and considering switching to oral finasteride or natural supplements like saw palmetto.

RU58841 is not recommended for use around children due to potential exposure risks. Alternatives like CB-03-01 might be considered, but further research is advised.

The user experienced good crown progress in 3 months using finasteride, collagen, vitamins B, C, D, zinc, and dermarolling. They are pleased with the results after a hair transplant on the front and mid scalp.

Fluridil's effectiveness and safety in treating hair loss are discussed, with higher concentrations showing potential success. Comparisons are made to other treatments like RU58841, Pyri, CB-03-01, and topical spironalactone.

User shared progress pictures after 2 months of using 1mg finasteride for hair loss. They are seeking feedback on any improvement.

The conversation discusses the best carrier for RU58841, comparing Ethanol and PEG400. The user seeks advice on which carrier is more effective.

The user is taking 0.5mg finasteride and 0.5mg Loniten orally daily, using Eucapil twice weekly, and Minoxidil foam once daily for hair loss. They believe Eucapil effectively stops hair loss despite side effects like breast growth.

Finasteride pills don't fully dissolve in a DIY topical solution due to fillers, resulting in residue. Users suggest shaking well before application and note that commercial solutions appear clearer.

Dr. Gabel doesn't use Verteporfin because it's not FDA approved. The user is getting FUT and wants to minimize scarring and maximize hair regrowth.

User started oral finasteride 0.33mg daily and later made a topical solution with cetirizine and stemoxydine. They experienced hair growth progress after 8-9 months and discussed factors affecting their results.

KX-826/pyrilutamide is undergoing an additional one-year safety and efficacy trial in China after a six-month study. Some participants speculate on the reasons for the extended trial and discuss the potential of other treatments.

The user is considering using CB or clascoterone for hair loss, potentially as an alternative to RU. They're also contemplating asking a dermatologist for topical clascoterone cream to apply to their temple.

The conversation discusses the safety of taking multivitamins and zinc tablets while using finasteride. Users share experiences with additional supplements like vitamin D3, K2, biotin, and oral minoxidil.

User shared 3 months progress using Fin (oral) and Min (foam) for hair loss. Others suggested adding derma rolling and discussed dosages and experiences.

The conversation discusses the safety and trustworthiness of ordering RU58841 from Lyphar Biotech in China, with a focus on pricing and reliability. The user is seeking advice on whether to proceed with the purchase or consider alternative sources.

OP is considering mixing finasteride pills with a 60ml bottle of Redensyl to create a topical treatment. The discussion focuses on the feasibility and effectiveness of this approach for hair loss.

The conversation discusses a new liposomal topical finasteride from Hasson and Wong, available in Canada and Italy, soon in the US, costing $40/month. It claims to reduce scalp DHT by 50% without affecting serum DHT, potentially benefiting those who can't tolerate oral finasteride or RU58841.

A user used oral finasteride and minoxidil for hair loss, seeing new hair growth under a microscope but no visible change. Commenters debated if the growth was real hair or fibers, and the user will update every 90 days.